Efficacy and Safety of Erlotinib Plus Cetuximab in Advanced Non-Small Cell Lung Cancer: A Phase I Trial
Non-small cell lung cancer (NSCLC) continues to pose significant therapeutic challenges, especially in patients without actionable EGFR mutations. While first-generation EGFR tyrosine kinase inhibitors (TKIs) like erlotinib have shown remarkable…